Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
The webinar featured perspectives from leading heart failure clinicians from across the
Ramesh Emani, MD, Interventional Heart Failure Cardiologist and Associate Professor of Clinical Medicine, Division of Cardiology, The Ohio State University– Columbus, OH Detlef Wencker, MD, Advanced Heart Failure Specialists– Dallas, TX Pat Correlli, PA-C, Chief Outpatient Physician’s Associate and Lead Clinician of Outpatient Congestive Heart Failure at MedStar Good Samaritan Hospital– Baltimore, MD
Panelists discussed the clinical and economic challenges associated with the current standards of care for managing fluid overload among heart failure patients, explored strategies for treating these patients in the outpatient setting, and shared their experiences with outpatient Aquadex UF therapy. Under the current standard of care, patients often have long hospital stays and hospitals are typically only partially reimbursed for the cost of care. Furthermore, hospitals receive no reimbursement for patients that are readmitted within 30 days of initial discharge. According to Premier Applied Sciences data, the average total unreimbursed cost per inpatient encounter is
“Outpatient ultrafiltration treatment with Aquadex presents a unique opportunity to break the cycle of heart failure readmissions, reducing the associated financial burden to healthcare systems, and improving patient quality of life,” said
According to the panelists, heart failure patients with fluid overload are often caught in a cycle where they are hospitalized, inadequately decongested, sent home, and then rehospitalized when congestion issues resurface. In fact, national data suggests that 24% of these patients will be rehospitalized within 30 days of discharge, and 50% within 90 days. In a study conducted by Lin et al., investigators evaluated the impact of repeat HF hospitalizations on all-cause mortality and determined the risk variables related to patient mortality. They found that mean survival time was 2.6, 1.8, 1.5, and 1.3 years after the first, second, third, and fourth hospitalization, respectively, and concluded that repeat hospitalizations were a strong predictor of mortality for existing patients with HF1.
The webinar panelists also shared how ultrafiltration with Aquadex therapy is being used in the outpatient setting to effectively address this challenge. According to
Patient satisfaction is another key benefit of ultrafiltration. “The feedback we’ve received has been almost universally positive. Patients really like having this as an option. And when we can tell them, you are going to get this treatment and then go home, it is all that much better,” said
The full webinar is available on the Nuwellis website and YouTube channel.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and predictable method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
1Andrew H Lin et al. Mil Med. 2017 Sep.
George Montague, CFA Chief Financial Officer, Nuwellis, Inc.firstname.lastname@example.org Matt Bacso, CFA Gilmartin Group LLCMatt.Bacso@gilmartinir.com MEDIA: Sarah LundbergHealth+Commerce email@example.com
Source: Nuwellis, Inc.